{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:05:02Z","timestamp":1648818302262},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.medcli.2017.07.018","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T16:50:39Z","timestamp":1507827039000},"page":"109-113","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pros y contras de la vacunaci\u00f3n frente a la enfermedad por meningococo B"],"prefix":"10.1016","volume":"150","author":[{"given":"Miguel","family":"Delgado Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela","family":"Dom\u00ednguez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2017.07.018_bib0180","unstructured":"Bolet\u00edn Epidemiol\u00f3gico Semanal. Centro Nacional de Epidemiolog\u00eda. Instituto de Salud Carlos III, 2007-2017."},{"key":"10.1016\/j.medcli.2017.07.018_bib0185","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/INF.0000000000001048","article-title":"The burden of pediatric invasive meningococcal disease in Spain (2008-2013)","volume":"35","author":"Rivero-Calle","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.medcli.2017.07.018_bib0190","doi-asserted-by":"crossref","first-page":"198.e1","DOI":"10.1016\/j.anpedi.2014.09.004","article-title":"Vacunaci\u00f3n frente al meningococo B. Posicionamiento del Comit\u00e9 Asesor de Vacunas de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda","volume":"82","author":"Moreno-P\u00e9rez","year":"2015","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.medcli.2017.07.018_bib0195","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","article-title":"Global incidence of serogroup B invasive meningococcal disease: A systematic review","volume":"15","author":"Sridhar","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medcli.2017.07.018_bib0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.anpedi.2015.12.001","article-title":"Enfermedad meningoc\u00f3cica invasiva en Navarra en la era de la vacuna conjugada antimeningoc\u00f3cica C","volume":"86","author":"Morales","year":"2017","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.medcli.2017.07.018_bib0205","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: Global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.medcli.2017.07.018_bib0210","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.medcli.2017.07.018_bib0215","doi-asserted-by":"crossref","first-page":"e0150721","DOI":"10.1371\/journal.pone.0150721","article-title":"Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: Analysis of the differences with other European countries","volume":"11","author":"Abad","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2017.07.018_bib0220","unstructured":"U. S. Preventive Services Task Force. Grade definitions after July 2012. [consultado 2 Feb 2017]. Disponible en: https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Name\/grade-definitions"},{"key":"10.1016\/j.medcli.2017.07.018_bib0225","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.medcli.2017.07.018_bib0230","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: A national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2017.07.018_bib0235","doi-asserted-by":"crossref","first-page":"520","DOI":"10.15585\/mmwr.mm6520a3","article-title":"Notes form the field: Outbreak of serogroup B meningococcal disease at a University - California, 2016","volume":"65","author":"Biswas","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl","key":"10.1016\/j.medcli.2017.07.018_bib0240","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jadohealth.2016.03.040","article-title":"Prevention of meningococcal infection in the United States: Current recommendations and future considerations","volume":"59","author":"Baker","year":"2016","journal-title":"J Adolescent Health"},{"key":"10.1016\/j.medcli.2017.07.018_bib0245","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/07448481.2017.1285772","article-title":"Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine","volume":"65","author":"Fiorito","year":"2017","journal-title":"J Am Coll Health"},{"key":"10.1016\/j.medcli.2017.07.018_bib0250","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the US in response to a University outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.medcli.2017.07.018_bib0255","first-page":"606","article-title":"Serogroup B meningococcal disease outbreak and carriage evaluation at a college - Rhode Island, 2015","volume":"64","author":"Soeters","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl","key":"10.1016\/j.medcli.2017.07.018_bib0260","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolescent Health"},{"key":"10.1016\/j.medcli.2017.07.018_bib0265","unstructured":"Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP). Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2017. [consultado 15 Feb 2017]. Disponible en: www.cdc.gov\/vaccines\/acip"},{"key":"10.1016\/j.medcli.2017.07.018_bib0270","doi-asserted-by":"crossref","first-page":"e20161890","DOI":"10.1542\/peds.2016-1890","article-title":"Recommendations for serogroup B meningococcal vaccine for persons 10 years and older","volume":"138","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.medcli.2017.07.018_bib0275","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged\u226510 years at increased risk for serogroup B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.medcli.2017.07.018_bib0280","doi-asserted-by":"crossref","first-page":"98.e1","DOI":"10.1016\/j.anpedi.2016.10.009","article-title":"Calendario vacunal de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda: recomendaciones para 2017","volume":"86","author":"Moreno-P\u00e9rez","year":"2017","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.medcli.2017.07.018_bib0285","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/20477724.2016.1195072","article-title":"Meningococcal B vaccination: Real-world experience and future perspectives","volume":"110","author":"Kuhdari","year":"2016","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.medcli.2017.07.018_bib0290","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: Targeting transmission & disease","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.medcli.2017.07.018_bib0295","doi-asserted-by":"crossref","first-page":"e0123383","DOI":"10.1371\/journal.pone.0123383","article-title":"Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunization programme","volume":"10","author":"Tirani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2017.07.018_bib0300","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.medcli.2017.07.018_bib0305","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","article-title":"Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France","volume":"34","author":"Lecocq","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.medcli.2017.07.018_bib0310","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.medcli.2017.07.018_bib0315","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/21645515.2015.1010885","article-title":"Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country","volume":"11","author":"Izquierdo","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.medcli.2017.07.018_bib0320","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00038-016-0821-0","article-title":"Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel","volume":"61","author":"Ginsberg","year":"2016","journal-title":"Int J Public Health"},{"key":"10.1016\/j.medcli.2017.07.018_bib0325","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","article-title":"Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero\u00ae to reduce meningococcal group B disease in Germany","volume":"34","author":"Christensen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.medcli.2017.07.018_bib0330","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1080\/21645515.2016.1160177","article-title":"Vaccinating Italian infants with a new multicomponent vaccine (Bexsero\u00ae) against meningococcal B disease: A cost-effectiveness analysis","volume":"12","author":"Gasparini","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.medcli.2017.07.018_bib0335","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.medcli.2017.07.018_bib0340","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.vaccine.2016.11.076","article-title":"Modelling the cost-effectiveness of catch-up \u2018MenB\u2019 (Bexsero) vaccination in England","volume":"35","author":"Christensen","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.medcli.2017.07.018_bib0345","unstructured":"Belmonte E. Vacunas: precios que no cuadran. El Mundo, 24 de febrero de 2017. Disponible en: http:\/\/www.elmundo.es\/grafico\/salud\/2017\/02\/22\/58ad7712ca4741391b8b45a5.html."},{"key":"10.1016\/j.medcli.2017.07.018_bib0350","unstructured":"Organizaci\u00f3n Panamericana de la Salud; Organizaci\u00f3n Mundial de la Salud. Programa ampliado de inmunizaciones. Precios de las vacunas para el a\u00f1o 2015, enmienda I [consultado 17 Mar 2017]. Disponible en: www.paho.org\/hq\/index.php?option=com_docman&task=doc."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317306450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317306450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T18:26:42Z","timestamp":1530642402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775317306450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0025775317306450"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2017.07.018","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pros y contras de la vacunaci\u00f3n frente a la enfermedad por meningococo B","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2017.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}